These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 15027060)

  • 1. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy.
    Dressler D
    Mov Disord; 2004 Mar; 19 Suppl 8():S92-S100. PubMed ID: 15027060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mouse diaphragm assay for detection of antibodies against botulinum toxin type B.
    Dressler D; Lange M; Bigalke H
    Mov Disord; 2005 Dec; 20(12):1617-9. PubMed ID: 16078216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical relevance of botulinum toxin antibodies].
    Dressler D
    Nervenarzt; 2008 Jun; 79 Suppl 1():36-40. PubMed ID: 18927965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody-induced failure of botulinum toxin type B therapy in de novo patients.
    Dressler D; Bigalke H
    Eur Neurol; 2004; 52(3):132-5. PubMed ID: 15479980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Antibody-induced failure of botulinum toxin therapy].
    Dressler D
    Nervenarzt; 2003 Dec; 74(12):1098-104. PubMed ID: 14647910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses?
    Dressler D; Münchau A; Bhatia KP; Quinn NP; Bigalke H
    Eur Neurol; 2002; 47(2):118-21. PubMed ID: 11844901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of therapeutic botulinum toxin preparations.
    Dressler D; Benecke R
    Disabil Rehabil; 2007 Dec; 29(23):1761-8. PubMed ID: 18033601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin type B de novo therapy of cervical dystonia: frequency of antibody induced therapy failure.
    Dressler D; Bigalke H
    J Neurol; 2005 Aug; 252(8):904-7. PubMed ID: 15761672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum toxin type B in antibody-induced botulinum toxin type A therapy failure.
    Dressler D; Bigalke H; Benecke R
    J Neurol; 2003 Aug; 250(8):967-9. PubMed ID: 12928917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Botulinum toxin antibody titres: measurement, interpretation, and practical recommendations.
    Dressler D; Rothwell JC; Bhatia K; Kopp B; Bigalke H; Adib Saberi F
    J Neurol; 2023 Mar; 270(3):1524-1530. PubMed ID: 36434127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Botulinum toxin: from drug to poison].
    Dressler D; Saberi FA
    Fortschr Neurol Psychiatr; 2009 Aug; 77 Suppl 1():S49-54. PubMed ID: 19685394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?
    Lange O; Bigalke H; Dengler R; Wegner F; deGroot M; Wohlfarth K
    Clin Neuropharmacol; 2009; 32(4):213-8. PubMed ID: 19620852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing botulinum toxin type a antibodies: clinical observations in patients with cervical dystonia.
    Rollnik JD; Wohlfarth K; Dengler R; Bigalke H
    Neurol Clin Neurophysiol; 2001; 2001(3):2-4. PubMed ID: 12396862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secondary nonresponsiveness to botulinum toxin A in cervical dystonia: the role of electromyogram-guided injections, botulinum toxin A antibody assay, and the extensor digitorum brevis test.
    Cordivari C; Misra VP; Vincent A; Catania S; Bhatia KP; Lees AJ
    Mov Disord; 2006 Oct; 21(10):1737-41. PubMed ID: 16874756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure.
    Schulte-Baukloh H; Bigalke H; Miller K; Heine G; Pape D; Lehmann J; Knispel HH
    Int J Urol; 2008 May; 15(5):407-15; discussion 415. PubMed ID: 18452456
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of botulinum toxin type F injections to treat torticollis in patients with immunity to botulinum toxin type A.
    Greene PE; Fahn S
    Mov Disord; 1993 Oct; 8(4):479-83. PubMed ID: 8232357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The EBD test--a clinical test for the detection of antibodies to botulinum toxin type A.
    Kessler KR; Benecke R
    Mov Disord; 1997 Jan; 12(1):95-9. PubMed ID: 8990060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.
    Sheean GL; Lees AJ
    J Neurol Neurosurg Psychiatry; 1995 Dec; 59(6):601-7. PubMed ID: 7500097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc.
    Dressler D; Hallett M
    Eur J Neurol; 2006 Feb; 13 Suppl 1():11-5. PubMed ID: 16417592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of cervical dystonia with botulinum toxin.
    Jankovic J
    Mov Disord; 2004 Mar; 19 Suppl 8():S109-15. PubMed ID: 15027062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.